Observational studyFrontiers in immunology2026
Malignancies in inborn errors of immunity: a retrospective-prospective study on a large Italian cohort of pediatric and adult patients.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inborn Errors of Immunity (IEI) are associated with an increased risk of malignancy due to impaired immune surveillance, genetic instability and chronic inflammation, However, comprehensive epidemiological data from large national cohorts remain limited. Methods: We conducted a multicenter, retrospective-prospective observational study involving 4,540 pediatric and adult patients with IEI, followed across 30 Italian referral centers, with the aim of evaluating those who developed cancer. Clinical, immunological, genetic, and oncological data were prospectively collected from October 2023 to October 2025, while the retrospective period covered January 2000 to September 2023. These findings were then compared with data from Italian population-based cancer registries (AIRTUM/AIRC). Results: Out of 4,540 patients with IEI, 248 developed malignancies: 133 females and 115 males, comprising 195 adults and 53 children. The overall prevalence of malignancy within the IEI cohort was 5.5% (95% CI: 4.8-6.2), with an incidence rate of 3.4 cases per 1,000 person-years. Common variable immunodeficiency represented the largest IEI subgroup and showed the highest prevalence of malignancy 11.7%, (95% CI: 10.1-13.4). Malignancies occurred significantly earlier than in the general Italian population, at a median age of 44 years (range: 1-82), particularly in patients with ataxia-telangiectasia, 8.5 years (range 4-23). In contrast, patients with IgA deficiency displayed the highest median age at first malignancy, 52 years (range: 18- 57), compared to other IEI categories. In 30.2% of cases, cancer represented the first clinical manifestation leading to the IEI diagnosis. A different oncological profile compared to Italian population-based data was observed, with Non-Hodgkin lymphoma (21.7%) as the most frequent cancer, followed by skin cancers (11.2%) and gastric adenocarcinoma (10.4%), The overall 10-year survival rate was 94%, with no significant differences between hematologic and solid malignancies, or between adult and pediatric cohorts. Conclusions: The multicenter, registry-based design of our study enabled a reliable estimation of cancer incidence among IEI patients and a direct comparison with the general population, while the longitudinal dataset provided valuable insights into the cancer spectrum and outcomes across different IEI subtypes. Tailored surveillance strategies, early IEI diagnosis and multidisciplinary management are essential to improve long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.